Incyte Corp
(MIL:1INCY)
€
66.84
0 (0%)
Market Cap: 13.69 Bil
Enterprise Value: 12.09 Bil
PE Ratio: 541.07
PB Ratio: 4.61
GF Score: 70/100 Incyte Corp at Guggenheim Biopharma's Next Decade Virtual Conference Transcript
Jun 28, 2021 / 03:00PM GMT
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
Okay. Hello, and welcome to this meeting with Incyte management as part of our 2021 Biopharma
Strategy Series. I'm Mike Schmidt, senior biotech analyst with Guggenheim. And with us today, we have Incyte's CEO, Herve Hoppenot as well as Christiana Stamoulis, the CFO. Welcome, guys, and thanks for joining us today.
Herve Hoppenot
Incyte Corporation - Chairman, President & CEO
No, thank you for inviting us.
Questions & Answers
Michael Werner Schmidt;
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
So Herve, maybe just starting out with a few general questions, and then I have a whole bunch of questions about the different products and pipeline assets. But starting out, as Jakafi continues to build a very strong commercial foundation for Incyte, could you just walk us through your long-term growth strategy and how it has evolved in recent years?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot